Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Haughney

Showing results (11-20 of 90) with videos related to

Pageof 9
Sort By:
Pharmacoeconomics|August 7, 2002
The cost effectiveness of chlorofluorocarbon-free beclomethasone dipropionate in the treatment of chronic asthma: a cost model based on a 1-year pragmatic, randomised clinical studyDavid Price, John Haughney, Martin Duerden, et al.
Primary Care Respiratory Journal : Journal of the General Practice Airways Group|June 30, 2009
The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma controlJane Clatworthy, David Price, Dermot Ryan, et al.
Current Medical Research and Opinion|October 7, 2004
An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE studyDavid Price, John Haughney, Adam Lloyd, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 28, 2016
Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPDMafalda Ramos, John Haughney, Nathaniel Henry, et al.
Respiratory Medicine|April 15, 2015
Serum periostin in smokers and never smokers with asthmaNeil C Thomson, Rekha Chaudhuri, Mark Spears, et al.
Allergy, Asthma & Immunology Research|October 4, 2011
Current control and future risk in asthma managementErika J Sims, David Price, John Haughney, et al.
British Journal of Clinical Pharmacology|June 19, 2014
'The more you link, the more you risk …' - a focus group study exploring views about data linkage for pharmacovigilanceYvonne M Hopf, Christine Bond, Jill Francis, et al.
NPJ Primary Care Respiratory Medicine|July 28, 2018
A review of asthma care in 50 general practices in Bedfordshire, United KingdomMark L Levy, Fiona Garnett, Adedayo Kuku, et al.
Expert Opinion on Drug Delivery|November 15, 2013
Switching from branded to generic inhaled medications: potential impact on asthma and COPDFederico Lavorini, Vincent Ninane, John Haughney, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 29, 2022
Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS StudyEnrico de Nigris, Catrin Treharne, Nick Brighton, et al.
Pageof 9

Showing results (11-20 of 90) with videos related to

Sort By:
Pageof 9
Pharmacoeconomics|August 7, 2002
The cost effectiveness of chlorofluorocarbon-free beclomethasone dipropionate in the treatment of chronic asthma: a cost model based on a 1-year pragmatic, randomised clinical studyDavid Price, John Haughney, Martin Duerden, et al.
Primary Care Respiratory Journal : Journal of the General Practice Airways Group|June 30, 2009
The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma controlJane Clatworthy, David Price, Dermot Ryan, et al.
Current Medical Research and Opinion|October 7, 2004
An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE studyDavid Price, John Haughney, Adam Lloyd, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 28, 2016
Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPDMafalda Ramos, John Haughney, Nathaniel Henry, et al.
Respiratory Medicine|April 15, 2015
Serum periostin in smokers and never smokers with asthmaNeil C Thomson, Rekha Chaudhuri, Mark Spears, et al.
Allergy, Asthma & Immunology Research|October 4, 2011
Current control and future risk in asthma managementErika J Sims, David Price, John Haughney, et al.
British Journal of Clinical Pharmacology|June 19, 2014
'The more you link, the more you risk …' - a focus group study exploring views about data linkage for pharmacovigilanceYvonne M Hopf, Christine Bond, Jill Francis, et al.
NPJ Primary Care Respiratory Medicine|July 28, 2018
A review of asthma care in 50 general practices in Bedfordshire, United KingdomMark L Levy, Fiona Garnett, Adedayo Kuku, et al.
Expert Opinion on Drug Delivery|November 15, 2013
Switching from branded to generic inhaled medications: potential impact on asthma and COPDFederico Lavorini, Vincent Ninane, John Haughney, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 29, 2022
Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS StudyEnrico de Nigris, Catrin Treharne, Nick Brighton, et al.
Pageof 9